Table 2.
The top three enriched pathways by robust DEGs in each brain region, determined using Enrichr and KEGG.
| Brain Region | Pathway | Alteration | p-Value | Adjusted p-Value |
Odd Ratio | Combined Score | Genes |
|---|---|---|---|---|---|---|---|
| Cerebellum | Mineral absorption | Up-regulated | 0.000005926 | 0.0007467 | 22.29 | 268.27 | MT2A, MT1A, MT1M, ATP2B4, MT1G |
| IL-17 signaling pathway | Up-regulated | 0.00005312 | 0.003347 | 13.75 | 135.34 | NFKBIA, CEBPB, CXCL1, S100A9, S100A8 | |
| NF-kappa B signaling pathway | Up-regulated | 0.01023 | 0.3936 | 7.09 | 32.49 | NFKBIA, GADD45A, CXCL1 | |
| Frontal cortex | Neuroactive ligand-receptor interaction | Down-regulated | 0.000001048 | 0.0002148 | 3.50 | 48.19 | GABBR2, GABRA1, CHRM3, EDN3, NPY5R, GABRA5, GABRA4, GRIK1, HTR2A, MCHR1, GABRG2, MCHR2, ADCYAP1, CORT, CCKBR, GLRB, SST, NMU, CRH, TAC3, TAC1, VIP, GABRD |
| GABAergic synapse | Down-regulated | 0.000002641 | 0.0002252 | 6.71 | 86.16 | GABBR2, GABRA1, GNG3, GNG2, SLC32A1, GABRA5, GABRA4, GAD2, PRKACB, GABRD, GABRG2 | |
| Complement and coagulation cascades | Up-regulated | 8.435 × 10−15 | 1.839 × 10−12 | 17.28 | 560.01 | C1QB, C1QA, C1S, CFH, C1R, C5AR1, CFI, F13A1, SERPINA5, C4B, C4A, C7, CFHR1, C3AR1, VSIG4, CFB, C1QC | |
| Hippocampus | Bacterial invasion of epithelial cells | Down-regulated | 0.0003395 | 0.01724 | 13.26 | 105.91 | CDC42, ARPC1A, ARPC4, MET |
| Synaptic vesicle cycle | Down-regulated | 0.0003567 | 0.01724 | 13.08 | 103.83 | ATP6V1G2, SLC32A1, SLC17A6, SLC1A6 | |
| Morphine addiction | Down-regulated | 0.0006406 | 0.01724 | 11.12 | 81.74 | GABRA1, SLC32A1, GNG4, PDE2A | |
| Entorhinal cortex | Morphine addiction | Down-regulated | 0.00008088 | 0.009868 | 12.52 | 118.00 | GABRB2, GABRA1, GNAS, ADCY1, GABRD |
| Gap junction | Down-regulated | 0.0008877 | 0.02926 | 10.15 | 71.31 | GNAS, ADRB1, ADCY1, TUBB4A | |
| GABAergic synapse | Down-regulated | 0.0009261 | 0.02926 | 10.03 | 70.04 | GABRB2, GABRA1, ADCY1, GABRD | |
| Temporal cortex | GABAergic synapse | Down-regulated | 4.244 × 10−10 | 9.295 × 10−8 | 12.30 | 265.54 | GABRB3, GABRB2, GABBR2, GABRA1, SLC12A5, PRKCB, GABRA5, GAD2, GABRG2, GLS, GNG3, GNG2, GABRD |
| Nicotine addiction | Down-regulated | 4.089 × 10−9 | 4.478 × 10−7 | 20.63 | 398.46 | GABRB3, GABRB2, GRIA2, GABRA1, GABRA5, SLC17A6, GABRD, GRIN2B, GABRG2 | |
| Retrograde endocannabinoid signaling | Down-regulated | 0.000001505 | 0.00007431 | 6.30 | 84.53 | GABRB3, GRIA2, GABRB2, MAPK9, GABRA1, GNG3, GNG2, PRKCB, GABRA5, SLC17A6, GABRD, GABRG2 |